Richard Chen Biography and Net Worth

Insider of Personalis

Dr. Chen joined Personalis in November 2011 as Chief Scientific Officer. A physician scientist, Dr. Chen has extensive expertise in systems biology, translational genomics, knowledge engineering, and scientific product development. Dr. Chen has co-founded and served on the board of several companies, including Ingenuity Systems, where he led the development of systems biology approaches to genomic data analysis for scientific discovery. Dr. Chen has also served on the clinical faculty at Stanford University School of Medicine where he led process and technology innovation for improved health care delivery. Dr. Chen received a BS in Computer Science from Stanford, and a MD from Stanford University School of Medicine. He also received a MS in biomedical informatics from Stanford. He completed his Chief Residency and Dermatology Specialty Training at Stanford and is board certified.

What is Richard Chen's net worth?: The estimated net worth of Richard Chen is at least $383,671.37 as of January 28th, 2025. Dr. Chen owns 123,367 shares of Personalis stock worth more than $383,671 as of April 6th. This net worth approximation does not reflect any other investments that Dr. Chen may own. Additionally, Dr. Chen receives a salary of $800,600.00 as Insider at Personalis. Learn More about Richard Chen's net worth.
How old is Richard Chen?: Dr. Chen is currently 53 years old. There are 3 older executives and no younger executives at Personalis. The oldest executive at Personalis is Mr. Aaron L. Tachibana, CFO & COO, who is 63 years old. Learn More on Richard Chen's age.
What is Richard Chen's salary?: As the Insider of Personalis, Inc., Dr. Chen earns $800,600.00 per year. There are 2 executives that earn more than Dr. Chen. The highest earning executive at Personalis is Mr. Christopher M. Hall, President, CEO & Director, who commands a salary of $963,750.00 per year. Learn More on Richard Chen's salary.
How do I contact Richard Chen?: The corporate mailing address for Dr. Chen and other Personalis executives is 1330 O`BRIEN DRIVE, MENLO PARK CA, 94025. Personalis can also be reached via phone at (650) 752-1300 and via email at investors@personalis.com. Learn More on Richard Chen's contact information.
Has Richard Chen been buying or selling shares of Personalis?: Richard Chen has not been actively trading shares of Personalis in the last ninety days. Most recently, Richard Chen sold 519 shares of the business's stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $5.79, for a transaction totalling $3,005.01. Following the completion of the sale, the executive vice president now directly owns 123,367 shares of the company's stock, valued at $714,294.93. Learn More on Richard Chen's trading history.
Who are Personalis' active insiders?: Personalis' insider roster includes Richard Chen (Insider), Aaron Tachibana (CFO), and John West (CEO). Learn More on Personalis' active insiders.
Are insiders buying or selling shares of Personalis?: In the last year, insiders at the sold shares 11 times. They sold a total of 14,941 shares worth more than $37,446.97. The most recent insider tranaction occured on January, 28th when CFO Aaron Tachibana sold 708 shares worth more than $4,099.32. Insiders at Personalis own 4.1% of the company. Learn More about insider trades at Personalis.
Information on this page was last updated on 1/28/2025.

Richard Chen Insider Trading History at Personalis

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/28/2025	Sell	519	$5.79	$3,005.01	123,367
11/18/2024	Sell	921	$3.79	$3,490.59	128,720
7/30/2024	Sell	524	$2.97	$1,556.28	127,227
5/17/2024	Sell	940	$1.38	$1,297.20	132,806
1/29/2024	Sell	526	$1.37	$720.62	128,870
12/15/2023	Sell	4,708	$1.47	$6,920.76	129,396
11/16/2023	Sell	940	$1.04	$977.60	124,104
7/31/2023	Sell	485	$2.26	$1,096.10	125,044
6/16/2023	Sell	4,817	$2.07	$9,971.19	125,529
5/17/2023	Sell	971	$1.98	$1,922.58	130,346
3/17/2023	Sell	1,314	$2.83	$3,718.62	131,317
1/31/2023	Sell	562	$2.20	$1,236.40	132,631
12/20/2022	Sell	1,750	$1.92	$3,360.00	133,193
12/2/2022	Sell	440	$2.60	$1,144.00	142,120
9/20/2022	Sell	1,581	$3.48	$5,501.88	143,855
7/28/2022	Sell	632	$3.91	$2,471.12	145,856
6/17/2022	Sell	1,565	$3.29	$5,148.85	146,488
6/15/2022	Sell	6,818	$3.24	$22,090.32	148,053
6/2/2022	Sell	421	$3.59	$1,511.39	154,871
3/2/2022	Sell	471	$10.18	$4,794.78
1/28/2022	Sell	705	$9.93	$7,000.65
12/17/2021	Sell	1,563	$12.80	$20,006.40
12/2/2021	Sell	419	$12.92	$5,413.48
9/17/2021	Sell	1,088	$21.25	$23,120.00
9/2/2021	Sell	291	$21.92	$6,378.72	82,122
8/6/2021	Sell	4,436	$21.22	$94,131.92
6/17/2021	Sell	1,101	$22.75	$25,047.75	74,980
6/2/2021	Sell	291	$21.57	$6,276.87	76,081
4/1/2021	Sell	40,000	$25.69	$1,027,600.00	62,094
3/17/2021	Sell	1,130	$26.73	$30,204.90	83,317
3/2/2021	Sell	345	$32.60	$11,247.00	84,447
12/17/2020	Sell	1,087	$36.37	$39,534.19	111,370
12/1/2020	Sell	40,000	$28.00	$1,120,000.00	152,750
10/1/2020	Sell	40,000	$22.06	$882,400.00	152,750
9/17/2020	Sell	1,120	$22.74	$25,468.80	115,298
9/2/2020	Sell	291	$22.99	$6,690.09	116,418
8/14/2020	Sell	32,000	$20.14	$644,480.00	148,709
6/22/2020	Sell	1,085	$12.37	$13,421.45	120,143
6/1/2020	Sell	289	$13.19	$3,811.91	121,211
3/9/2020	Sell	1,000	$7.84	$7,840.00	60,000
2/25/2020	Sell	101,000	$8.77	$885,770.00	160,000

See Full Table

Richard Chen Buying and Selling Activity at Personalis

Personalis Company Overview

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.

Today's Range

Now: $3.11

$2.93

$3.21

50 Day Range

MA: $4.38

$3.11

$6.04

2 Week Range

Now: $3.11

$1.14

$7.20

Volume

924,788 shs

Average Volume

949,012 shs

Market Capitalization

$274.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.89

Richard Chen Biography and Net Worth

What is Richard Chen's net worth?

How old is Richard Chen?

What is Richard Chen's salary?

How do I contact Richard Chen?

Has Richard Chen been buying or selling shares of Personalis?

Who are Personalis' active insiders?

Are insiders buying or selling shares of Personalis?